Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Regains Compliance With Nasdaq Listing Rules

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies announced today that it has regained compliance with the Nasdaq's $1 minimum bid price requirement.

In July, Genetic Technologies said that it had been notified that its shares faced delisting from the exchange for trading below $1 for 30 consecutive business days. The company's stock has now regained listing compliance, having a minimum closing bid price per share of $1 or above for 10 consecutive business days.

During late morning trading, shares of Genetic Technologies were up nearly 12 percent at $1.3869.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more